The US Food and Drug Administration (FDA) has granted preliminary approval for a new vaccine that would provide the first protection against the rare but deadly coronavirus.
The vaccine is called AZT-5, and it was developed by the drugmaker Merck.
The company says the vaccine would be safe and effective for patients over age 65, but that there will be some side effects.
The approval means the vaccine will be licensed by the FDA in the US and Canada, and the drugmakers have been working on the vaccine since last year.
The AZT vaccine is the only one to target the coronaviruses coronaviral and influenza viruses.
The US government is not sure whether the vaccine can provide protection against these two deadly diseases.
But a small trial of the vaccine found it was highly effective against the two viruses.
In the trial, vaccinated people showed a 70% reduction in the number of new coronaviroc cases and an 80% reduction on the number that were not vaccinated.
A trial of a vaccine against the coronovirus was also conducted in Denmark, which was a surprise because that country had only been able to vaccinate a small percentage of people with the virus.
The new vaccine is expected to be ready in a year.
The FDA is expected on Thursday to grant the final approval to Merck’s vaccine for the US.
It will take more than two years for the FDA to approve a vaccine for humans, and a trial of it for a vaccine would take years.
Merck is also developing a vaccine that it hopes to sell in the first half of 2019.
However, the agency has been slow to approve vaccines for other infectious diseases, including tuberculosis, which killed almost 1 million people in the United States in 2016 and was the leading cause of death among children and young adults in the developed world.
It is unclear whether Merck has reached a final agreement with the US government on the AZT vaccines.
The agency could delay the approval, which would likely delay the full implementation of the vaccines.
The new vaccine will protect against the virus, and its safety and effectiveness will depend on how it is administered, according to Merk.
The safety of the AZTs vaccine has been tested in large trials of older people.
It was also found to be effective in reducing the number and severity of coronavirence among children, but not adults.
In a separate study published in the New England Journal of Medicine, the researchers found that the vaccine did not provide protection at all against the most common form of the coronavia virus, coronavira, or the virus that causes pneumonia.
A new vaccine might have to be more expensive, but it is not known if the price tag would increase dramatically, and Merck could decide to stop the development of the new vaccine before it is approved.
Follow David Loh on Twitter: @DavidLohCNN